Retham Technologies has raised $1.5M in seed funding to push its heparin-induced thrombocytopenia diagnostic toward the clinic. The round drew Talents Fund, Golden Angels Investors and Milwaukee Venture Partners Inc.
The Milwaukee-area company, founded in 2017, is developing HITDx, an in vitro diagnostic aimed at diagnosing HIT earlier and more accurately than the tests hospitals rely on today. The stakes are high: HIT is a dangerous reaction to the blood thinner heparin that can lead to amputation, stroke or death, and the widely used PF4 ELISA tests carry high false-positive rates that push thousands of patients onto alternative anticoagulants with worse bleeding risks.
